The uptake of recombinant factor VIII in the Netherlands

British Journal of Haematology

Volumn 119, Issue 2, 2002, Pages 332-341

  Zwart van Rijkom, J E F ^a,b,d   Plug, I ^c   Rosendaal, F R ^c   Leufkens, H G M ^a   Broekmans, A W ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Haemophilia; Patient preference; Physician preference; Product choice; Recombinant Factor VIII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEALTH SURVEY; HEMOPHILIA A; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; CHILD; FACTOR VIII; FEMALE; HEMATOLOGY; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT PARTICIPATION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; RECOMBINANT PROTEINS;

EID: 0036436880     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03903.x     Document Type: Article

References (17)

1. Addiego, J., Kasper, C., Abildgaard, C., Hilgartner, M., Lusher, J., Glader, B. & Aledort, L. (1993) Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet, 342, 462-464.
2. Agence Francaise de Sécurité Sanitaire des Produits de Santé (AFSSAPS) (2000) Risk Analysis of New Variant Creutzfeldt-Jakob disease Transmission by Blood and Blood Products. AFSAPPS, Saint-Denis.
3. Anonymous (2000) US approval for Kogenate FS. Scrip, p 20.
4. Anonymous (2001) Bayer suspends product release for Kogenate FS3, Transfusion Today, 11-12.
5. Briët, E. & Mauser-Bunschoten, E.P. (1997) Revision consensus haemophilia: Treatment and responsibility. Nederlandse Vereniging van Haemophilia Patients. Ned Tijdschr Geneeskd, 141, 2566-2571.
6. Gale, E.A. (1989) Hypoglycaemia and human insulin. Lancet, 2, 1264-1266.
7. Hoyer, L.W. (1994) Haemophilia A. New England Journal of Medicine, 330, 38-47.
8. Lusher, J.M., Arkin, S., Abildgaard, C.F. & Schwartz, R.S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine, 328, 453-459.
9. Mannucci, P.M. & Tuddenham, E.G. (2001) The haemophilias: from royal genes to gene therapy. New England Journal of Medicine, 344, 1773-1779.
10. Mauser-Bunschoten, E.P. (1995) Complications of haemophilia care. PhD Thesis. Department of Medicine, Utrecht University, The Netherlands.
11. Mauser-Bunschoten, E.P., Bresters, D., van Drimmelen, A.A., Roosendaal, G., Cuypers, H.T.M., Reesink, H.W., van der Poel, C.L., van den Berg, H.M. & Lelie, P.N. (1995) Hepatitis C infection and viremia in Dutch haemophilia patients. Journal of Medical Virology, 45, 241-246.
12. Mauser-Bunschoten, E.P., Roosendaal, G. & van den Berg, H.M. (2001) Product choice and haemophilia treatment in the Netherlands. Haemophilia, 7, 96-98.
13. van Rijkom, J., Leufkens, H., Crommelin, D., Rutten, F.F.H. & Broekmans, A.W. (1999) Assessment of biotechnology drugs: What are the issues? Health Policy, 47, 255-274.
14. Rosendaal, F.R., Smit, C. & Briët, E. (1991) Haemophilia treatment in historical perspective: A review of medical and social developments. Annals of Hematology, 62, 5-15.
15. Triemstra, A.H.M. (1996) Medical and psychosocial aspects of haemophilia. PhD Thesis. Department of Medicine, Free University, Amsterdam.
16. de Wit, H.J.C. & Mauser-Bunschoten, E.P. (1995) Recombinant DNA factor VIII. Pharm Weekbl, 130, 756-759.
17. Wolff, S.P. (1992) Trying times for human insulin. Nature, 356, 375-376.